Table 1.
Descriptive characteristics of the study groups.
| VO (n = 75) | VAI (n = 53) | IO (n = 60) | IAV (n = 36) | |
|---|---|---|---|---|
| Age, median, (%25–75) | 35 (28–42) | 31 (29–41) | 31 (27–40) | 30 (26–39) |
| Gender, female, n (%) | 43 (57.3) | 30 (56.6) | 34 (48.6) | 25 (69.4) |
| Body mass index | 24 (22–27) | 25 (22–28) | 25 (23–28) | 24 (22–27) |
| Comorbidity present, n(%) | 16 (21.3) | 20 (37.7) | 14 (20.3) | 9 (25.0) |
| Days from COVID-19 diagnosis to blood collection | NA | 167 (135–333) | 162 (125–296) | 52 (48–59) |
| Days from second dose of vaccination to blood collection | 46 (41–47) | 44 (42–46) | NA | 109 (104–109) |
| Days from COVID-19 diagnosis to second dose of vaccination | 94 (62–261) | 55 (45–59) | ||
| Hospitalized, n (%) | NA | 8 (15.1) | 3 (5.0) | 0 |
| Comorbidity, n (%) | 16 (21.3) | 20 (37.7) | 14 (23.7) | 9 (25.0) |
| Asthma | 4 (5.3) | 2 (3.8) | 2 (3.3) | 4 (11.1) |
| Thyroid disorders | 2 (2.7) | 3 (5.7) | 4 (6.7) | 1 (2.8) |
| Allergic rhinitis | 0 | 7 (13.2) | 1 (1.7) | 1 (2.8) |
| Hypertension | 2 (2.7) | 3 (5.7) | 1 (1.7) | 1 (2.8) |
| Diabetes | 1 (1.3) | 2 (3.8) | 0 | 1 (2.8) |
| Malignancy | 2 (2.7) | 1 (1.9) | 1 (1.7) | 0 |
| Rheumatologic | 0 | 3 (5.7) | 0 | 1 (2.8) |
| Miscellaneous | 9 (12.0) | 0 | 5 (8.3) | 1 (2.8) |
| Adverse events | ||||
| Any adverse event after first or second dose | 23 (30.7) | 18 (34.0) | – | 12 (33.3) |
| Fatigue | 14 (18.7) | 1 (1.9) | – | 7 (19.4) |
| Myalgia | 8 (10.7) | 2 (3.8) | – | 4 (11.1) |
| Pain at injection site | 4 (5.3) | 3 (5.7) | – | 3 (8.3) |
| Sore throat | 4 (5.3) | 0 | – | 1 (2.8) |
| Fever | 0 | 1 (1.9) | – | 2 (5.6) |
| Dyspnea | 1 (1.3) | 1 (1.9) | – | 1 (2.8) |
| Rash | 0 | 1 (1.9) | – | 1 (2.8) |
| Other | 7 (9.3) | 9 (17.0) | – | 3 (8.3) |
Abbreviations: VO; Vaccine Only, VAI; Vaccine After Infection, IO; Infection Only, IAV; Infection After Vaccination, NA; not applicable.